Scout Investments Inc. raised its stake in Novartis AG (NYSE:NVS) by 1.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 197,105 shares of the company’s stock after buying an additional 3,715 shares during the quarter. Scout Investments Inc.’s holdings in Novartis were worth $15,936,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of NVS. Fisher Asset Management LLC lifted its position in shares of Novartis by 2.8% during the fourth quarter. Fisher Asset Management LLC now owns 6,816,625 shares of the company’s stock worth $572,324,000 after purchasing an additional 183,641 shares in the last quarter. Northern Trust Corp lifted its position in shares of Novartis by 2.3% during the first quarter. Northern Trust Corp now owns 4,089,571 shares of the company’s stock worth $330,642,000 after purchasing an additional 90,010 shares in the last quarter. BlackRock Inc. lifted its position in shares of Novartis by 8.2% during the fourth quarter. BlackRock Inc. now owns 4,015,562 shares of the company’s stock worth $337,146,000 after purchasing an additional 305,221 shares in the last quarter. Thomaspartners Inc. lifted its position in shares of Novartis by 3.0% during the first quarter. Thomaspartners Inc. now owns 3,842,741 shares of the company’s stock worth $310,686,000 after purchasing an additional 110,361 shares in the last quarter. Finally, Aristotle Capital Management LLC lifted its position in shares of Novartis by 7.2% during the fourth quarter. Aristotle Capital Management LLC now owns 3,195,134 shares of the company’s stock worth $268,263,000 after purchasing an additional 215,584 shares in the last quarter. 10.96% of the stock is currently owned by institutional investors.
Several brokerages have recently issued reports on NVS. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a research report on Monday, April 9th. Zacks Investment Research cut shares of Novartis from a “hold” rating to a “sell” rating in a research report on Thursday, June 7th. Deutsche Bank reissued a “neutral” rating on shares of Novartis in a research report on Tuesday, April 10th. Credit Suisse Group raised shares of Novartis from an “underperform” rating to a “neutral” rating in a report on Friday, May 25th. Finally, ValuEngine cut shares of Novartis from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. Four analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $89.81.
In related news, major shareholder Institutes For Biomed Novartis purchased 766,666 shares of the company’s stock in a transaction on Monday, April 23rd. The shares were bought at an average cost of $15.00 per share, for a total transaction of $11,499,990.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.01% of the company’s stock.
NYSE:NVS traded up $0.19 during mid-day trading on Thursday, hitting $75.98. The stock had a trading volume of 1,301,600 shares, compared to its average volume of 1,665,358. The stock has a market cap of $175.66 billion, a price-to-earnings ratio of 15.80, a price-to-earnings-growth ratio of 1.65 and a beta of 0.76. Novartis AG has a twelve month low of $74.11 and a twelve month high of $94.19. The company has a quick ratio of 0.91, a current ratio of 1.17 and a debt-to-equity ratio of 0.33.
Novartis (NYSE:NVS) last issued its earnings results on Thursday, April 19th. The company reported $1.28 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.25 by $0.03. The firm had revenue of $12.69 billion for the quarter, compared to analysts’ expectations of $12.45 billion. Novartis had a net margin of 16.04% and a return on equity of 16.23%. The firm’s revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.13 earnings per share. equities analysts anticipate that Novartis AG will post 5.24 EPS for the current year.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.